Inhibikase Therapeutics, Inc. filed a Current Report on Form 8-K with the Securities and Exchange Commission on September 8, 2026, to furnish an updated corporate presentation. The filing indicates that the company intends to use this updated presentation during meetings with investors, analysts, and other interested parties.
The company provided Exhibit 99.1, which serves as the updated corporate overview. This document includes a detailed disclaimer regarding forward-looking statements, noting that the presentation contains projections of future clinical studies, regulatory approvals, and financial condition. It also highlights the risks and uncertainties that could cause actual results to differ materially from those anticipated.
The presentation focuses on the company's lead candidate, IKT-001, which is being developed as a novel prodrug of imatinib for the treatment of pulmonary arterial hypertension (PAH). The overview details the high unmet medical need in PAH, citing a five-year mortality rate of approximately 30%.
According to the filing, IKT-001 is designed to retain the efficacy potential of imatinib while improving gastrointestinal tolerability. The document references Phase 3 IMPRES and Phase 2 studies that indicated a placebo-adjusted 6-minute walk distance (6MWD) gain of 45 meters. The company notes that while imatinib has demonstrated efficacy in reversing PAH in animal models, it is not currently approved for PAH due to adverse events and a high discontinuation rate.
The filing outlines the Phase 3 IMPROVE-PAH study, which is currently enrolling across 26 countries and 46 sites. The study design incorporates a titration-based approach to manage patients to the highest tolerable dose. The company states it has orphan drug designation and intellectual property runway extending to 2044.
The corporate overview also profiles the executive team, including Chief Executive Officer Mark Iwicki, Chief Medical Officer Dr. Chris Cabell, and Chief Scientific Officer Dr. John Adams.
